| |
Tuesday, June 17, 2025 | 11am ET / 8am PT We invite you to join industry experts to explore advanced process analytical technologies (PAT), and how they are transforming bioprocessing. Register now.
|
|
Today’s Big NewsJun 12, 2025 |
|
Monday, June 16, 2025 | 12pm ET / 9am PT Join a candid and informative discussion between precision medicine experts. They will share lessons learned and concrete opportunities to transform clinical trial design, execution and outcomes. Register now.
|
|
| By Heather Landi HHS Secretary Robert F. Kennedy Jr. named eight new members to serve on the Centers for Disease Control and Prevention's vaccine advisory panel just two days after he removed all 17 sitting members of the key advisory committee. |
|
|
|
By Angus Liu Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem following a phase 3 flop and "moderating" new-to-brand prescription growth. But the company's top executives don't see things that way. |
By Gabrielle Masson After dropping its only clinical-stage candidate last month, ADC Therapeutics is shutting down a U.K. R&D site and laying off 30% of its workforce. |
By Andrea Park Sprout Pharmaceuticals is once again under fire from the FDA’s Office of Prescription Drug Promotion. |
|
Wednesday, June 18, 2025 | 12pm ET / 9am PT In this webinar, we will present two new methods for blood preservation that can be easily implemented at any clinical site just after the patient’s blood collection. Register to learn more.
|
|
By Conor Hale Medtronic has landed on a new brand for the planned spinout of its diabetes division, and it didn’t have to look very far. |
By Eric Sagonowsky Belgium's UCB is adding its name to the mix of drugmakers planning to grow their manufacturing footprints in the U.S. |
By James Waldron BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech at $1.25 billion. |
By Kevin Dunleavy For the second time in nine months, a Delaware judge has sided with Syntimmune shareholders over AstraZeneca, granting a $181 million award. The decision comes on top of a $130 million judgment issued in September of last year. |
By Conor Hale Wandercraft's series D will help boost clinical adoption of its suits for rehabilitation and mobility as well as support its industrial programs. |
By Nick Paul Taylor Havas Media Network has set up an advertising marketplace to help companies reach patients who are cut off from healthcare by geographic or socioeconomic barriers. |
By Zoey Becker GSK's multiple myeloma antibody drug conjugate Blenrep is up for an FDA decision in July. If approved, the drug would complete a return to the U.S. market after it was withdrawn following a failed confirmatory study in 2022. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," we explore how employers are rethinking their approach to employee wellbeing—integrating mental, physical and financial health strategies to better reach the people who need them most. |
|
|---|
|
|
|
Supported by 30 years of experience conducting complex Phase I & II clinical trials, QPS Miami supports special populations and diverse indications like NASH, diabetes, obesity and oncology. Learn More.
|
|
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
